Sugi Predict

Sugi Predict / Compounds / SCHEMBL1163802

SCHEMBL1163802

SCHEMBL1163802

Fc1cc2ncccc2cc1Br

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 2/20 0.53
▸ CYP1A2 P05177 1/20 0.53
▸ CYP2C19 P33261 1/20 0.53
▸ NPC1 O15118 6/20 0.47
▸ RAB9A P51151 2/20 0.47
▸ POLB P06746 2/20 0.47
▸ PDGFRB P09619 1/20 0.46
▸ PDGFRA P16234 1/20 0.46
▸ CASP6 P55212 1/20 0.44
▸ ALDH1A1 P00352 6/20 0.44
▸ CASP1 P29466 2/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ MAPT P10636 2/20 0.44
▸ CASP7 P55210 1/20 0.44
▸ NR4A2 P43354 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ TP53 P04637 1/20 0.44
▸ HSP90AA1 P07900 1/20 0.44
▸ HSP90AB1 P08238 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30540041 1.00 HTT (0.53) HTTCYP1A2CYP2C19NPC1RAB9A
SCHEMBL20265531 0.92 HTT (0.53) HTTCYP1A2CYP2C19NPC1RAB9A
SCHEMBL5833750 0.84 NPC1 (0.54) HTTCYP1A2CYP2C19NPC1RAB9A
SCHEMBL28370443 0.77 CASP6 (0.62) HTTCYP1A2CYP2C19NPC1RAB9A
SCHEMBL22324148 0.77 ALDH1A1 (0.53) HTTCYP1A2CYP2C19NPC1RAB9A
SCHEMBL3587363 0.77 ALDH1A1 (0.53) HTTCYP1A2CYP2C19NPC1RAB9A
SCHEMBL30456422 0.77 ALDH1A1 (0.53) HTTCYP1A2CYP2C19NPC1RAB9A
SCHEMBL13692754 0.77 NPC1 (0.47) HTTCYP1A2CYP2C19NPC1RAB9A
SCHEMBL12489798 0.77 NPC1 (0.47) HTTCYP1A2CYP2C19NPC1RAB9A
SCHEMBL29556845 0.77 CASP6 (0.62) HTTCYP1A2CYP2C19NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260015337-A1 COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION TRAWSFYNYDD THERAPEUTICS INC (US) 2026-01-15 — — US disclosed
EP-4622967-A1 COMPOUNDS THAT INHIBIT PKMYT1 Exelixis, Inc. (US) 2025-10-01 — — EP disclosed
US-20250152574-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF BIOGEN MA INC. 2025-05-15 — — US disclosed
EP-4539844-A2 COMPOUNDS FOR TREATMENT OF A CORONAVIRUS INFECTION Trawsfynydd Therapeutics, Inc. (US) 2025-04-23 — — EP disclosed
US-20250115578-A1 AROMATIC FUSED RING NAV1.8 INHIBITOR, AND USE THEREOF CHENGDU KANGHONG PHARMACEUTICAL CO., LTD. (CN) 2025-04-10 — — US disclosed
CN-119731156-A Emopanamide binding protein inhibitors and uses thereof 渤健马萨诸塞州股份有限公司 2025-03-28 — — CN disclosed
US-20250099462-A1 Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor HUTCHISON MEDIPHARMA LTD (CN) 2025-03-27 — — US disclosed
CN-119604290-A Compounds for the treatment of coronavirus infections 特劳斯芬尼德治疗股份有限公司 2025-03-11 — — CN disclosed
WO-2025036479-A1 KINESIN KIF18A INHIBITOR AND USE THEREOF 上海湃隆生物科技有限公司 2025-02-20 — — WO disclosed
EP-4479384-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF Biogen MA Inc. (US) 2024-12-25 — — EP disclosed
EP-2084162-A2 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS SGX Pharmaceuticals, Inc. (US) 2009-08-05 — — EP disclosed
EP-2081937-A2 TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS SGX Pharmaceuticals, Inc. (US) 2009-07-29 — — EP disclosed
US-20090156594-A1 HETEROCYCLIC KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2009-06-18 — — US disclosed
WO-2008144767-A1 HETEROCYCLIC KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-11-27 — — WO disclosed
WO-2008051805-A2 TRIAZOLO-PYRIDAZINE PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-05-02 — — WO disclosed
WO-2008051808-A2 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-05-02 — — WO disclosed
WO-2008051808-A2 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-05-02 — — WO disclosed
WO-2007132308-A1 TRIAZOLOPYRAZINE DERIVATIVES USEFUL AS ANTI-CANCER AGENTS PFIZER PRODUCTS INC. (US) 2007-11-22 — — WO disclosed
US-20070265272-A1 TRIAZOLOPYRAZINE DERIVATIVES PFIZER INC. 2007-11-15 — — US disclosed
US-20070265272-A1 TRIAZOLOPYRAZINE DERIVATIVES PFIZER INC. 2007-11-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265272-A1 TRIAZOLOPYRAZINE DERIVATIVES JAK2, ABL1, CCND2 HTT 1869/4885CYP1A2 1235/4885CYP2C19 2471/4885
US-20250115578-A1 AROMATIC FUSED RING NAV1.8 INHIBITOR, AND USE THEREOF SCN8A, SCN10A, SCN7A HTT 1076/4885CYP1A2 2188/4885CYP2C19 2273/4885
US-20260015337-A1 COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION ACE2, ACE, TMPRSS2 HTT 2418/4885CYP1A2 210/4885CYP2C19 94/4885
US-20090156594-A1 HETEROCYCLIC KINASE MODULATORS MAP3K20, MAP4K2, MAP3K13 HTT 1612/4885CYP1A2 4005/4885CYP2C19 3797/4885
US-20250152574-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF EBPL, EBP, CREBBP HTT 3979/4885CYP1A2 4765/4885CYP2C19 4865/4885
US-20250099462-A1 Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor KCNJ11, NISCH, CYP4Z1 HTT 2558/4885CYP1A2 133/4885CYP2C19 314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.